Impact of baseline abnormal liver enzymes in the outcome of COVID-19 infection

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorFARIAS, Joao Pedro
dc.contributor.authorCODES, Liana
dc.contributor.authorVINHAES, Diana
dc.contributor.authorAMORIM, Ana Paula
dc.contributor.authorD'OLIVEIRA, Ricardo Cruz
dc.contributor.authorFARIAS, Alberto Queiroz
dc.contributor.authorBITTENCOURT, Paulo Lisboa
dc.date.accessioned2024-04-05T19:31:34Z
dc.date.available2024-04-05T19:31:34Z
dc.date.issued2023
dc.description.abstractBackground: Little is known about the significance of liver function tests (LFT) abnormalities in COVID-19 and their impact on disease outcomes. The aims of the study were to evaluate abnormalities of LFT in patients with COVID-19 and their impact on disease severity, mortality, and correlation with leukocyte markers of inflammation. Methods: All patients with COVID-19 admitted to the emergency department (ED) of a single reference center were retrospectively evaluated. Data were collected using an electronic medical database covering the following variables: demographics, baseline complete blood count (CBC) and ratios, neutrophillymphocyte (NLR) and monocyte-lymphocyte ratios (MLR), systemic immune-inflammation index (SII), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels. Disease severity was defined by the presence of organ failure (OF) or requirement for intensive care unit (ICU) support. Mortality was considered as patient death during hospitalization. Results: A total of 1,539 subjects (799 women, mean age 57 +/- 18 years) with COVID-19 were evaluated. Abnormal AST and/or ALT were seen in 50% of them, with a frequency and magnitude that significantly correlated with leukocyte count and ratios. Both LFT were significantly associated with requirement for hospital and ICU admission and mortality. High AST levels were significantly associated with the presence, number, and types of OFs and in-hospital length of stay (LOS). Elevated ALT was also significantly associated with the aforementioned variables, with the exception of OFs presence, circulatory failure and LOS. Conclusions: LFT abnormalities are frequently seen in COVID-19 patients, reflect SARS-CoV-2 associated inflammation and may predict adverse outcomes. LFT may be useful to aid decision-making in the ED for hospital admission or scheduled outpatient reevaluation.eng
dc.description.indexPubMed
dc.description.indexScopus
dc.description.indexDimensions
dc.description.indexWoS
dc.identifier.citationTRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, v.8, article ID 5, 9p, 2023
dc.identifier.doi10.21037/tgh-22-41
dc.identifier.eissn2415-1289
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/58874
dc.language.isoeng
dc.publisherAME PUBLISHING COMPANYeng
dc.relation.ispartofTranslational Gastroenterology and Hepatology
dc.rightsopenAccesseng
dc.rights.holderCopyright AME PUBLISHING COMPANYeng
dc.subjectLiver enzymeseng
dc.subjectCOVID-19eng
dc.subjectmortalityeng
dc.subject.otherinjuryeng
dc.subject.wosGastroenterology & Hepatologyeng
dc.titleImpact of baseline abnormal liver enzymes in the outcome of COVID-19 infectioneng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalFARIAS, Joao Pedro:Univ Salvador Unifacs, Salvador, BA, Brazil
hcfmusp.author.externalCODES, Liana:Portuguese Hosp Bahia, Salvador, BA, Brazil; Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil
hcfmusp.author.externalVINHAES, Diana:Portuguese Hosp Bahia, Salvador, BA, Brazil
hcfmusp.author.externalAMORIM, Ana Paula:Portuguese Hosp Bahia, Salvador, BA, Brazil
hcfmusp.author.externalD'OLIVEIRA, Ricardo Cruz:Portuguese Hosp Bahia, Salvador, BA, Brazil; Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil
hcfmusp.author.externalBITTENCOURT, Paulo Lisboa:Portuguese Hosp Bahia, Salvador, BA, Brazil; Bahiana Sch Med & Publ Hlth, Salvador, BA, Brazil
hcfmusp.citation.scopus0
hcfmusp.contributor.author-fmusphcALBERTO QUEIROZ FARIAS
hcfmusp.description.articlenumber5
hcfmusp.description.volume8
hcfmusp.origemWOS
hcfmusp.origem.dimensionspub.1152268387
hcfmusp.origem.pubmed36704646
hcfmusp.origem.scopus2-s2.0-85176219204
hcfmusp.origem.wosWOS:000878473000001
hcfmusp.publisher.citySHATINeng
hcfmusp.publisher.countryPEOPLES R CHINAeng
hcfmusp.relation.referenceBernsmeier C, 2020, ALIMENT PHARM THER, V52, P855, DOI 10.1111/apt.15932eng
hcfmusp.relation.referenceBernstein D, 2021, WORLD J GASTROENTERO, V27, P7350, DOI 10.3748/wjg.v27.i42.7350eng
hcfmusp.relation.referenceBertolini A, 2020, HEPATOLOGY, V72, P1864, DOI 10.1002/hep.31480eng
hcfmusp.relation.referenceBloom PP, 2021, HEPATOLOGY, V73, P890, DOI 10.1002/hep.31326eng
hcfmusp.relation.referenceCai QX, 2020, J HEPATOL, V73, P566, DOI 10.1016/j.jhep.2020.04.006eng
hcfmusp.relation.referenceChen LY, 2020, J DIGEST DIS, V21, P512, DOI 10.1111/1751-2980.12925eng
hcfmusp.relation.referenceDing ZY, 2021, J HEPATOL, V74, P1295, DOI 10.1016/j.jhep.2020.12.012eng
hcfmusp.relation.referenceDu M, 2022, CLIN RES HEPATOL GAS, V46, DOI 10.1016/j.clinre.2021.101793eng
hcfmusp.relation.referenceEkpanyapong S, 2022, J VIRAL HEPATITIS, V29, P4, DOI 10.1111/jvh.13590eng
hcfmusp.relation.referenceFajgenbaum DC, 2020, NEW ENGL J MED, V383, P2255, DOI 10.1056/NEJMra2026131eng
hcfmusp.relation.referenceGabrielli M, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10020192eng
hcfmusp.relation.referenceHu BY, 2021, J MED VIROL, V93, P250, DOI 10.1002/jmv.26232eng
hcfmusp.relation.referenceHundt MA, 2020, HEPATOLOGY, V72, P1169, DOI 10.1002/hep.31487eng
hcfmusp.relation.referenceJothimani D, 2020, J HEPATOL, V73, P1231, DOI 10.1016/j.jhep.2020.06.006eng
hcfmusp.relation.referenceKovalic AJ, 2021, HEPATOLOGY, V73, P1521, DOI 10.1002/hep.31472eng
hcfmusp.relation.referenceKulkarni AV, 2020, ALIMENT PHARM THER, V52, P584, DOI 10.1111/apt.15916eng
hcfmusp.relation.referenceLeal T, 2021, EUR J GASTROEN HEPAT, V33, P691, DOI 10.1097/MEG.0000000000002152eng
hcfmusp.relation.referenceLei F, 2020, HEPATOLOGY, V72, P389, DOI 10.1002/hep.31301eng
hcfmusp.relation.referenceLeo M, 2022, DIGEST LIVER DIS, V54, P565, DOI 10.1016/j.dld.2021.12.014eng
hcfmusp.relation.referenceLowsby R, 2015, EMERG MED J, V32, P531, DOI 10.1136/emermed-2014-204071eng
hcfmusp.relation.referenceMcConnell MJ, 2021, J HEPATOL, V75, P647, DOI 10.1016/j.jhep.2021.04.050eng
hcfmusp.relation.referencePerazzo H, 2017, ANN HEPATOL, V16, P269, DOI 10.5604/16652681.1231586eng
hcfmusp.relation.referencePhipps MM, 2020, HEPATOLOGY, V72, P807, DOI 10.1002/hep.31404eng
hcfmusp.relation.referencePirola CJ, 2020, LIVER INT, V40, P2038, DOI 10.1111/liv.14500eng
hcfmusp.relation.referencePozzobon FM, 2021, HEPATOL INT, V15, P493, DOI 10.1007/s12072-021-10141-6eng
hcfmusp.relation.referenceQi FR, 2020, BIOCHEM BIOPH RES CO, V526, P135, DOI 10.1016/j.bbrc.2020.03.044eng
hcfmusp.relation.referenceQi XL, 2020, J HEPATOL, V73, P455, DOI 10.1016/j.jhep.2020.04.010eng
hcfmusp.relation.referenceSharma A, 2021, ANN HEPATOL, V21, DOI 10.1016/j.aohep.2020.10.001eng
hcfmusp.relation.referenceShehab M, 2021, BMJ OPEN GASTROENTER, V8, DOI 10.1136/bmjgast-2020-000571eng
hcfmusp.relation.referenceSiddiqui MA, 2022, DIGEST DIS SCI, V67, P2577, DOI 10.1007/s10620-021-07007-0eng
hcfmusp.relation.referenceSobotka LA, 2022, DIGEST DIS SCI, V67, P4204, DOI 10.1007/s10620-021-07230-9eng
hcfmusp.relation.referenceSultan S, 2020, GASTROENTEROLOGY, V159, P320, DOI 10.1053/j.gastro.2020.05.001eng
hcfmusp.relation.referenceWagner J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89340-yeng
hcfmusp.relation.referenceWeber S, 2021, GUT, V70, P1925, DOI [10.1136/gutjnl-2020-323800, 10.1136/gutjnl-2020-]eng
hcfmusp.relation.referenceYadav DK, 2021, GUT, V70, P807, DOI 10.1136/gutjnl-2020-322072eng
hcfmusp.relation.referenceYoussef M, 2020, J MED VIROL, V92, P1825, DOI 10.1002/jmv.26055eng
hcfmusp.relation.referenceYu DD, 2021, VIROL J, V18, DOI 10.1186/s12985-021-01593-1eng
hcfmusp.relation.referenceZhao WB, 2022, J MED VIROL, V94, P1886, DOI 10.1002/jmv.27627eng
hcfmusp.scopus.lastupdate2024-05-17
relation.isAuthorOfPublication08e1a16a-ae48-493b-9c8c-cfd318d04d90
relation.isAuthorOfPublication.latestForDiscovery08e1a16a-ae48-493b-9c8c-cfd318d04d90
Arquivos
Coleções
Artigos e Materiais de Revistas Científicas - FM/MGT
Artigos e Materiais de Revistas Científicas - COVID-19